Get the Stockscreener App
670.21
0.18%
1.21
Idexx Laboratories Inc stock is traded at $670.21, with a volume of 574.10K.
It is up +0.18% in the last 24 hours and up +5.48% over the past month.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
See More
Previous Close:
$669.00
Open:
$670.18
24h Volume:
574.10K
Relative Volume:
1.26
Market Cap:
$21.35B
Revenue:
$4.17B
Net Income/Loss:
$1.03B
P/E Ratio:
53.13
EPS:
12.6148
Net Cash Flow:
$940.22M
1W Performance:
-5.93%
1M Performance:
+5.48%
6M Performance:
+29.36%
1Y Performance:
+59.64%
1-Day Range:
$665.25
$681.63
1-Week Range:
$665.25
$719.25
52-Week Range:
$356.14
$735.00
Idexx Laboratories Inc Stock (IDXX) Company Profile
Name
Idexx Laboratories Inc
Sector
Industry
Phone
(207) 556-0300
Address
ONE IDEXX DRIVE, WESTBROOK, ME
Compare IDXX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IDXX
Idexx Laboratories Inc
|
670.21 | 53.42B | 4.17B | 1.03B | 940.22M | 12.61 |
|
TMO
Thermo Fisher Scientific Inc
|
576.03 | 213.09B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
225.51 | 155.71B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
A
Agilent Technologies Inc
|
143.84 | 40.97B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
MTD
Mettler Toledo International Inc
|
1,396.45 | 28.37B | 3.87B | 829.75M | 847.84M | 39.48 |
|
WAT
Waters Corp
|
376.63 | 22.50B | 2.91B | 622.64M | 620.14M | 10.48 |
Idexx Laboratories Inc Stock (IDXX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-25 | Upgrade | Stifel | Hold → Buy |
| Oct-01-25 | Initiated | UBS | Neutral |
| Aug-05-25 | Reiterated | BTIG Research | Buy |
| Jul-01-25 | Initiated | Jefferies | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Outperform |
| Jul-25-24 | Initiated | BTIG Research | Buy |
| Jan-30-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
| Dec-04-23 | Upgrade | Cleveland Research | Neutral → Buy |
| Aug-02-23 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Jul-25-22 | Downgrade | Stifel | Buy → Hold |
| Jul-21-22 | Upgrade | Goldman | Neutral → Buy |
| Jul-12-22 | Initiated | Piper Sandler | Overweight |
| May-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-08-22 | Initiated | Atlantic Equities | Overweight |
| Nov-18-21 | Initiated | Morgan Stanley | Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-12-21 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-17-21 | Initiated | Barclays | Overweight |
| Sep-09-19 | Initiated | Goldman | Neutral |
| May-23-19 | Initiated | Guggenheim | Buy |
| Nov-02-18 | Reiterated | BofA/Merrill | Buy |
| May-07-18 | Reiterated | Stifel | Buy |
| Jan-16-18 | Initiated | Piper Jaffray | Overweight |
| Aug-23-17 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-28-17 | Upgrade | CL King | Neutral → Buy |
| Feb-03-17 | Downgrade | Feltl & Co. | Hold → Sell |
| Sep-29-16 | Resumed | BofA/Merrill | Neutral |
| Aug-16-16 | Reiterated | Stifel | Buy |
| Aug-03-16 | Upgrade | Northcoast | Sell → Neutral |
| Jul-20-16 | Reiterated | Canaccord Genuity | Buy |
| Apr-19-16 | Reiterated | Canaccord Genuity | Buy |
| Apr-01-16 | Initiated | CL King | Neutral |
| Mar-21-16 | Reiterated | Stifel | Buy |
| Feb-04-16 | Initiated | Credit Suisse | Outperform |
| Oct-29-15 | Reiterated | Stifel | Buy |
| Aug-28-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Aug-13-15 | Reiterated | Stifel | Buy |
| Jul-23-15 | Reiterated | Canaccord Genuity | Buy |
View All
Idexx Laboratories Inc Stock (IDXX) Latest News
Why IDEXX Laboratories Inc. stock is a must watch in 2025Portfolio Risk Summary & Growth Focused Entry Point Reports - newser.com
How robust is IDEXX Laboratories Inc. (IX1) stock financial positionPortfolio Profit Report & Short-Term Trading Opportunity Alerts - newser.com
Why retail investors favor IDEXX Laboratories Inc. stockJuly 2025 News Drivers & Safe Entry Trade Signal Reports - newser.com
Can IDEXX Laboratories Inc. (IX1) stock retain market dominanceWeekly Gains Report & Risk Controlled Stock Pick Alerts - newser.com
Will IDEXX Laboratories Inc. stock outperform growth indexesJuly 2025 Retail & Technical Confirmation Trade Alerts - newser.com
Why IDEXX Laboratories Inc. stock could benefit from AI revolutionJuly 2025 Weekly Recap & Safe Swing Trade Setups - newser.com
Is IDEXX Laboratories Inc. stock cheap at current valuation2025 Investor Takeaways & Long-Term Safe Investment Plans - newser.com
Is IDEXX Laboratories Inc. stock attractive for ETFsTrend Reversal & Reliable Entry Point Alerts - newser.com
Is IDEXX Laboratories Inc. stock trading at a premium valuation2025 Price Targets & Low Drawdown Investment Strategies - newser.com
Why IDEXX Laboratories Inc. (IX1) stock stays undervaluedJobs Report & Precise Swing Trade Alerts - newser.com
IDEXX Laboratories (IDXX) Price Target Increased by 10.84% to 773.18 - Nasdaq
Quantitative breakdown of IDEXX Laboratories Inc. recent moveMarket Weekly Review & Reliable Volume Spike Trade Alerts - newser.com
What machine learning models say about IDEXX Laboratories Inc.Rate Hike & Fast Entry Momentum Trade Alerts - newser.com
Is IDEXX Laboratories Inc. stock supported by strong cash flows - newser.com
Does IDEXX Laboratories Inc. fit your quant trading modelMarket Weekly Review & Low Risk Growth Stock Ideas - newser.com
Is IDEXX Laboratories Inc. (IX1) stock prepared for digital transitionTrade Performance Summary & Weekly Watchlist of Top Performers - newser.com
Will IDEXX Laboratories Inc. stock recover after recent dropEarnings Risk Summary & Smart Investment Allocation Insights - newser.com
Trend analysis for IDEXX Laboratories Inc. this weekJuly 2025 Recap & Growth Focused Stock Reports - newser.com
IDEXX Laboratories Amends Credit Agreement for Flexibility - TipRanks
Building trade automation scripts for IDEXX Laboratories Inc.2025 Institutional Moves & Weekly Breakout Stock Alerts - newser.com
Idexx Laboratories Shares Reach New Highs Amid Insider Selling Activity - AD HOC NEWS
Idexx Laboratories Inc Stock (IDXX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.60%
3.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):